Alaunos Therapeutics Inc

Explore Alaunos Therapeutics’ breakthrough preclinical data on ALN1003—a non‑hormonal, orally‑administered obesity treatment that could diversify its oncology‑focused pipeline and unlock new growth opportunities.

Alaunos Therapeutics Inc., a clinical-stage biotech company, faces financial challenges and market volatility despite its innovative adoptive TCR-T cell therapy for cancer treatment.

Alaunos Therapeutics Inc. has caught the attention of PMGC Capital LLC, which has acquired a 5.09% stake in the company, sparking speculation about a potential acquisition.